Project Grant R21AI182936
Award Date
7/25/25
Completion Date
6/30/27
Dollars Obligated
$364K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $143,450 to support research on developing therapies for treating viral-induced acute lung injury. The primary focus is on evaluating the therapeutic efficacy of combinations of PPARG agonist and RXR ligand compounds in cotton rat models of influenza and respiratory syncytial virus (RSV) infection. The research...
This Project Grant award of $565,834 from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (CFDA 93.837 Cardiovascular Diseases Research), aims to investigate the long-term impact of early-life respiratory syncytial virus (RSV) infection on the development of childhood asthma. The research will focus on understanding how RSV infection can cause epigenetic modifications in lung epithelial cells that lead to persistent changes in the lung's...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $249,276 to the University of San Francisco (USF) to assess the real-world effectiveness of maternal respiratory syncytial virus (RSV) vaccination. The project aims to evaluate the impact of the recently licensed maternal RSV vaccine in preventing RSV-associated lower respiratory tract infections (LRTIs) in infants,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $347,608 to Biotherapeutics, Inc. to develop a novel, oral, once-daily, immunoregulatory therapeutic for the treatment of asthma. The key objectives are to: 1) characterize the therapeutic efficacy and route of administration of the drug candidate in mouse models of asthma, and 2) determine the translational ability of the therapeutic...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $481,249.00 to Vanderbilt University Medical Center to conduct research on enhancing airway epithelial barrier function and anti-viral immune responses to reduce respiratory viral infection-induced asthma exacerbations. The key objectives are to: 1) Define how the dual GLP-1 receptor/GIP receptor agonist tirzepatide increases airway...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $429,000 to the University of Texas at Dallas (UTD) to conduct research on the relationship between the chemical composition and viability of bioaerosols containing respiratory viruses like RSV. The 2-year project aims to: 1) determine the spatial distribution of chemicals and pathogens in bioaerosols using advanced...
This $163,080 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a multidimensional analysis of the regulatory T cell (Treg) response in children with severe viral pneumonia. The primary investigator will conduct research to determine if Treg cells have impaired reparative functions during severe viral pneumonia in juvenile mice, investigate how the age-specific lung microenvironment affects...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $740,709 to the University of Utah to conduct research on how early-life viral infections can lead to the development of childhood asthma. The key objectives are to define the cellular and molecular mechanisms by which viral-induced inflammation programs hyperactivated type 2 innate lymphoid cells (ILC2s) in the lung, and determine if these hyperactivated ILC2s...
This Project Grant award of $781,129 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports a 5-year study to validate and extend an integrated host-microbe (IHM) diagnostic approach for accurately diagnosing lower respiratory tract infections (LRTIs) in critically ill children. The study aims to: 1) validate the performance of the existing IHM LRTI diagnostic classifier, 2) develop a novel host gene expression...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $433,125 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Ohio State University. The funding supports research to investigate the role of the influenza A virus (IAV) protein PB1-F2 in causing hypoxemia (low blood oxygen levels) and acute respiratory distress syndrome (ARDS) in influenza infections. The research aims to define the effects of PB1-F2 on alveolar type II (ATII)...